Mateon Therapeutics Inc. buy klostergang
Start price
03.06.15
/
50%
€1.36
Target price
07.12.15
€1.70
Performance (%)
-39.82%
End price
07.12.15
€0.82
Summary
This prediction ended on 07.12.15 with a price of €0.82. The BUY prediction by klostergang for Mateon Therapeutics Inc. performed very badly with a performance of -39.82%. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Mateon Therapeutics Inc. | - | - | - | - |
| iShares Core DAX® | -3.509% | -8.747% | -0.997% | 48.496% |
| iShares Nasdaq 100 | -2.782% | -0.632% | 14.223% | 78.812% |
| iShares Nikkei 225® | -2.038% | -6.841% | 24.866% | 51.559% |
| iShares S&P 500 | -2.598% | -2.230% | 9.200% | 60.509% |
Comments by klostergang for this prediction
In the thread Mateon Therapeutics Inc. diskutieren
Die FDA billigt PFS als primären Endpunkt der Phase-3-Studie :
http://seekingalpha.com/article/3228966-there-is-significant-upside-ahead-for-oxigene
(Vom Mitglied beendet)